Bio + Health

Bio Breakthroughs of 2020, as Heard on Journal Club

Lauren Richardson and a16z editorial Posted December 19, 2020

There is no question that the biggest, most significant scientific story of 2020 is the work to understand, treat, and vaccinate against COVID-19. But the story doesn’t end there. Across bio, but particularly at the powerful interface of biology and technology, there have been a number of significant advances this year. Our podcast show “Journal Club” — which was launched in April on the a16z Podcast and is now part of Bio Eats World — curates groundbreaking new scientific articles, digs into the details and the key implications, and covers how to translate these new insights from paper to practice.

As the host of Journal Club, I’ve spent the last 9 months immersed in the scientific literature (well, 5 years and 9 months if you count my time as an editor of PLOS Biology!), selecting the articles to discuss and the guests to join each episode. For articles, we look for the big leaps forward, not just in our knowledge of biology, but in our applications of that information. Our guests include both the a16z bio team as well as leading academic experts. I want to say an extra special thank you to them — and to those of you who have been listening! (And for those who have not, be sure to subscribe in your favorite podcast app). Here’s a selection of episodes that represent some of the biggest bio breakthroughs of 2020. 

New ways to treat disease

Defeating Type 1 Diabetes

with Ronald Evans and Lauren Richardson

There are two key hurdles that must be crossed to treat — and possibly cure — Type 1 diabetes: one is the loss of the pancreatic beta cells that produce insulin and thus regulate metabolism; and the second is the autoimmune response that targets and destroys those beta cells. In this Nature article, the authors address both of these problems, in part by using the same tricks cancer cells use to evade the immune system. This work could represent a revolutionary treatment for a life-long condition.

Reversing Parkinson’s with New Neurons

with Xiang-Dong Fu and Lauren Richardson

Parkinson’s Disease is characterized by the loss of specific neurons in the brain. So what if we could just grow new neurons to replace those lost to disease? That is exactly what Xiang-Dong Fu and colleagues did in this groundbreaking Nature article. They reprogrammed astrocytes, another common cell type in the brain, to convert into neurons, which were able to functionally replace the lost ones in a mouse model of the disease. This work — which was inspired by an accidental observation in the lab — could lead to a substantial improvement for patients.

Degrading Drugs for Problematic Proteins

with Carolyn Bertozzi and Lauren Richardson

This article in Nature takes us one big step closer to making the term “undruggable” a thing of the past. The new therapeutic modality described in this work grabs onto disease-causing proteins and drags them into the lysosome, where they are degraded. This method for targeting problem proteins has a number of advantages over existing techniques and can hit proteins that were never accessible to drugs before.

Bioengineering Birth

with Anthony Atala and Lauren Richardson

Infertility is a common problem, and when caused by issues with the uterus there are few treatment options. This article in Nature Biotechnology makes a huge leap towards a solution by creating a bioengineered uterus that can be delivered surgically into a recipient (in this case, a rabbit) and function as the normal uterus does. This work is the first to show that a bioengineered uterus can support pregnancy and birth — and could address an unmet clinical need.

Slaying the Sleeper Cells of Aging with CAR T

with Jorge Conde, Andy Tran, and Lauren Richardson

One of the hallmarks of aging is the accumulation of senescent cells (also called zombie cells, though I don’t like that analogy because they were never dead). These cells can cause a number of issues — with the most troublesome being the inflammation that they induce, which underlies a number of age-related conditions. Removing these senescent cells is hypothesized (and supported by work in mice) to remedy these conditions and improve health. In this Nature article, the authors engineer T cells that can specifically target and destroy senescent cells, and show that these senescent-targeting T cells can treat several mouse models of disease. Could these cells be a major breakthrough in treating aging and improving healthspan?

Using CRISPR to Prevent Coronavirus and Influenza Infection

with Vijay Pande, Andy Tran, and Lauren Richardson

These days, when people think of CRISPR, they think of its application in genome editing (understandably, as this was the discovery recognized by the Nobel Prize this year). But CRISPR originally evolved not to edit genomes, but to destroy them. In this article, published in Cell, the authors use CRISPR for its original purpose: targeting and trashing viral genomes. Specifically, they program CRISPR to attack the genomes of SARS-CoV-2 and influenza A. This work could be the basis for a whole new way to treat these diseases: prophylactically

New tools to explore biology (and one day treat disease)

Turning a Toxin into a Genome Editing Tool

with Jorge Conde, Andy Tran, and Lauren Richardson

There are now multiple generations of systems that can edit the genome (zinc fingers, TALENS, and CRISPR, to name a few), but none of these has been able to touch one particular part of the human genome: the mitochondrial genome (mtDNA). Mutations in mtDNA cause ~150 different diseases in humans, so remedying these with genome editing is alluring, but until this Nature article, seemed impossible. The authors tamed a bacterial toxin and engineered it to target the mtDNA to perform precision edtis — creating a new way to study these diseases and one day possibly treating them with gene therapy.

Modeling Mysterious Brain Structures

with Madeline Lancaster and Lauren Richardson

Brain organoids are an exciting new tool for studying structures that were — at least until now — inaccessible. One of these structures is the choroid plexus, which plays a number of critical roles in the brain but which has been historically understudied due to its location and complexity. In this Science article, the authors created an organoid model of the choroid plexus which recapitulated its key functions, including secreting the cerebrospinal fluid. Importantly, this organoid model has a number of potential applications, including in assessing the safety of new drugs.

Finding New Antibiotics with Machine Learning, What Coronavirus Structures Tell Us

With Vijay Pande, Andy Tran, Judy Savitskaya, and Lauren Richardson

In the very first episode of journal club, we covered three articles. In the first, published in Cell, the authors used  a deep learning approach to identify novel antibiotics. Not only were these antibiotics newly identified, but they had structures that were totally unique amongst known antibiotics, demonstrating the power of AI for generating unique insights. The second and third articles, published in Cell and Science, respectively, were two of the first works to describe the structure of the SARS-CoV-2 spike protein. Most of the vaccines in development for COVID-19 target this exact protein (including the Pfizer/BioNTech and Moderna vaccines) and understanding its structure was a key first step in understanding which regions to attack.

Building beyond biology

From Insect Eyes to Nanomaterials

with Judy Savitskaya and Lauren Richardson

There are seemingly countless uses for nanostructured materials, as they can provide a surface with a wide range of properties (reflective/anti-reflective, hydrophobicity/hydrophilicity, just to name a few). To date, creating such nanostructured materials requires advanced manufacturing methods. But in this Nature article, the authors devise a way to create nanomaterials with specific properties using just two ingredients that assemble themselves into reproducible patterns. This breakthrough was inspired by studying insect eyes (and the work of Alan Turing!), and could have major implications in biomanufacturing.

Building a Better Chloroplast

with Judy Savitskaya and Lauren Richardson

One of the foundations for life on earth is the ability to convert energy from the sun and carbon dioxide from the air into energy stored in carbohydrates. One of the key enzymes that mediates this conversion is called Rubisco, but it really hasn’t changed much since those early days. The problem is that Rubisco is very slow; so in this article (which builds off of this 2016 article, both published in Science), the authors re-engineered the entire carbon-fixing pathway to get around Rubsico, creating faster fixation. These re-engineered pathways could be the basis of synthetic chloroplasts that could extract more carbon dioxide from the air and fuel faster growing crops.

Surprising answers to long-standing questions

How to Win an Evolutionary Arms Race

with Harmit Malik and Lauren Richardson

Forget what you learned in Genetics 101, this eLife article flips commonly held ideas about how mutations impact protein function on their head; the senior author even observed that “My intuition before we did this experiment would have been to be the opposite in both respects.” These new insights — which came from studying a key protein involved in the immune response to HIV — could contribute to development of novel, and possibly curative, treatments to the virus that causes AIDS.

Architecting an Aggressive Cancer

with Elaine Fuchs and Lauren Richardson

One question that continues to stump scientists studying cancer is why some cancers are aggressive and why some are benign? This Nature article uncovers an unexpected resolution to this question in skin cancer: tissue architecture. It turns out that aggressive skin cancers build structures that create physical forces on the tumor and the surrounding cells that promote invasion from the initial site into new tissues. This work highlights the need to consider how cancers manipulate the mechanical forces of their environment as a critical part of their pathophysiology. 

Decoding Developmental Disorders

with Vineeta Agarwala and Lauren Richardson

This article, published in Nature, demonstrates the power of genetic data-sharing programs. By combining sequencing data from a diagnostic lab, a research study, and a tertiary care center, the authors were able to uncover 28 new genes linked to severe developmental disorders. This work provides invaluable information to patients and their families, as well as inspires future research efforts and therapies.

 

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Bio + Health

Streamlining the Patient Referrals Chain with Trey Holterman

David Haber, Trey Holterman, Jay Rughani, Kris Tatiossian, and Olivia Webb
Bio + Health

From Chaos to Clarity in Data with Malinka Walaliyadde

Malinka Walaliyadde, Julie Yoo, Olivia Webb, and Kris Tatiossian
Bio + Health

Superaging with Eric Topol

Eric Topol and Vijay Pande
Bio + Health

What Super Agers Reveal About Preventing Disease

Eric Topol and Vijay Pande
Bio + Health

Fueling Innovation with Data with Arif Nathoo

Arif Nathoo, Jorge Conde, Jay Rughani, Olivia Webb, and Kris Tatiossian

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.